Clinical trials: phaseI/II
Primary Myelofibrosis (PMF), Post-Polycythaemia Vera
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis
- Trial name
- NCT00910728
- Testing
- AZD1480
- Where
- 3 sites in United States, France
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Scleritis, Orbital Disease
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
The purpose of this study is to assess the safety and tolerability of Rituximab in refractory scleritis and non-infectious orbital inflammation.
- Trial name
- NCT00415506
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Oregon Health and Science University
Colorectal Cancer
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
We performed a phase I/II study of CPT-11/5FU/l-LV in advanced colorectal cancer, to determine the optimal dose of CPT-11 and to estimate the safety and efficacy of this regimen
- Trial name
- NCT00209625
- Testing
- irinotecan, leucovorin, fluorouracil
- Where
- Japan
- Volunteers
- 23 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Chronic Lymphocytic Leukemia
A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia
This is a prospective, multicenter, open label, non-randomized, phase I/II-study to define safety and efficacy of BRL combination in relapsed/refractory patients and to recommend a safe and efficacious dose for future phase…
- Trial name
- CLL2P (NCT01558167)
- Testing
- Bendamustine, Rituximab, Lenalidomide
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- German CLL Study Group
ALL, Adult, AML, Adult
A Study of BN104 in the Treatment of Acute Leukemia
The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.
- Conditions
- ALL, Adult, AML, Adult, Acute Leukaemia, KMT2A Rearrangement
- Trial name
- NCT06052813
- Testing
- BN104 monotherapy, BN104 monotherapy - rp2d
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
Stage IIIA Non-small Cell Lung Cancer
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue in patients with…
- Trial name
- NCT01076231
- Testing
- proton beam radiation therapy, cisplatin, etoposide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hormone Refractory Prostate Cancer, Prostate Cancer
Study Evaluating the Safety and Tolerability of L-377202
The primary purpose of this study is to (1) determine the maximally tolerated dose (MTD) of L-377202 administered once every 3 weeks, (2) evaluate the safety and tolerability of L-377202 including the dose-limiting adverse…
- Trial name
- NCT00987753
- Testing
- L-377202
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Alabama at Birmingham
Retinopathy of Prematurity
PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity
This is an open-label, single-arm phase I/II trial to evaluate the safety and efficacy of Rho-associated protein kinase(ROCK) inhibitor Ripasudil eye drops for preterm infants with Retinopathy of Prematurity(ROP).
- Trial name
- NCT04621136
- Testing
- Ripasudil ophthalmic solution 0.4%
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Kyushu University
Severe Sepsis and Septic Shock
Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients
The purpose of this study is to investigate the effect of an extracorporeal application of a bed-side bioreactor containing human donor granulocytes on the course and outcome of septic shock in humans.
- Trial name
- EISS-1 (NCT00818597)
- Testing
- EISS
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Rostock
Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma
A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
This is an open-label, multicenter, Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of EMB-07 combination therapy in adult patients with aggressive B-cell…
- Conditions
- Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07, phaseI/II
- Trial name
- NCT07432022
- Testing
- EMB07, Rituximab/Gemcitabine/Oxaliplatin
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.